| Name | Title | Contact Details |
|---|
entrinsic bioscience is a recognized leader in the development, manufacturing and commercialization of disruptive, science-derived amino-acid technologies that are clinically-proven to deliver better health outcomes in a broad range of therapeutic areas including gut health, hydration, skin and respiratory health.
ELEVAI LABS, INC. is a biotechnology company developing cutting-edge regenerative skincare applications. The company solves the unmet needs in the regenerative aesthetics space through a combination of cutting-edge science and next-generation consumer applications. Elevai Labs develops state-of-the-art topic anesthetic and pharmaceutical-grade skin care for the physician-dispensed market, with a focus on leveraging stem cell exosome technology.
Dechra Pharmaceuticals PLC is a global leader in veterinary pharmaceuticals, dedicated exclusively to the veterinary market. Founded in 1997, the company has a rich history dating back to 1819. Dechra develops, manufactures, and markets high-quality pharmaceutical products and services aimed at improving animal health and welfare. It operates in 24 countries and distributes products in over 50 countries. The company offers a diverse portfolio of prescription-only veterinary medicines for companion animals and horses, focusing on areas such as endocrinology, dermatology, and critical care. Dechra also provides water-soluble antibiotics, poultry vaccines, and specialized diets. Its services division includes laboratories that support veterinary diagnostics. With a strong emphasis on understanding veterinarians needs, Dechra provides training and scientific resources to enhance animal care.
ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.
Rockland Immunochemicals is a Gilbertsville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.